News Detail
Maryland, 12 Feb 2025: A pair of Chinese manufacturers with active pharmaceutical ingredients that were previously shipped to the U.S. have landed in the FDA’s crosshairs thanks to quality shortfalls, poor testing standards and more.
The FDA earlier t......
View Details
Source : Fierce Pharma
U.S. FDA
FDA warning letter
FDA inspection
active pharmaceutical ingredients
drug manufacturing
Manufacturing Facilities
China
import alert
Facilities
Fierce Pharma Homepage
Pharma
Manufacturing
Related News
- ‘Sodium Phosphates Enema BP,’ claimed to treat ‘Convulsions’ seized (12-02-2025)
- Substandard Medicines issue raised in Rajya Sabha (12-02-2025)
- Enhancing chemotherapy efficacy; targeting drug resistance with novel molecules: Study (12-02-2025)
- Over 3k brands hit pharma mkt, cancer drug 'Enhertu' tops in sales (12-02-2025)
- Falsely manufactured RedFer-XT Tablets seized in for violating drug regulations (12-02-2025)
- Health ministry issues final notification on extension of revised Schedule M deadline for MSMEs (12-02-2025)
- Anticancer Drug Pharmacokinetics may differ by Sex (12-02-2025)
- Biovet’s BIOLUMPIVAXIN® vaccine for Lumpy Skin disease receives CDSCO License (12-02-2025)
- Drug Trafficking Network busted on Amritsar-Jamnagar Expressway; Three Individuals, Including a Woman, Arrested (12-02-2025)
- NPPA fixes retail price of 42 formulations, revise prices based on review orders (11-02-2025)